Dr. Andreas Rummelt

InterPharmaLink AG

Dr. Andreas Rummelt, PhD. has been the Chief Executive Officer and Partner\Managing Partner at InterPharmaLink AG since 2011. Dr. Rummelt served has been the Group Head of Quality Assurance and Technical Operations at Novartis Institutes for BioMedical Research, Inc. from December 2008 to 2010. He joined Sandoz Pharma Ltd. in Switzerland in 1985 and served various positions of increasing responsibility in drug development including Global Head of Technical Research & Development during 1994 to 1999. He was a Member of the Novartis Executive Committee from 2006 to 2010. He served as the First Group Head of Quality Assurance and Technical Operations at Novartis AG from December 1, 2008 to February 2010. Dr. Rummelt served as Chief Executive Officer of Sandoz Canada Inc. He served as the Chief Executive Officer of Sandoz International GmbH at Novartis India Ltd. from November 1, 2004 to December 2008. He served as the Chief Executive Officer of Sandoz Inc. and Head of Sandoz at Novartis AG from November 1, 2004 to December 2008. He served as the Head of Worldwide Technical Research and Development (TRD) from 1994 to 1999 and Head of Global Technical Operations at Novartis Pharma AG, a division of Novartis AG from 1999 to October 2004. Dr. Rummelt served as the Head of Corporate Technical R&D since 1994. He served at Sandoz from 1985 to 1994 and served various positions in Development. From 1985 to 1994, he served as Laboratory Head and as Group Head and finally as Department Head in the area of Drug Delivery Systems Technology. He has more than 25 years of experience in the pharmaceutical industry, primarily focusing on drug development, technical operations, quality assurance and global manufacturing strategy. He served as Vice Chairman of Acino International AG since April 4, 2013 and served as its Director since April 1, 2011. He serves as a Director of Habasit AG. He has been a Director of Alexion Pharmaceuticals, Inc. since February 2010. He has been a Non Executive Director of Selcia Limited since February 22, 2011. He serves as a Director and Member of Scientific Advisory Board at Xellia Pharmaceuticals AS. He serves as a Director of Xellia Pharmaceuticals ApS and Famar Health Care Services, GR. He has been a Member of Supervisory Board at LEUKOCARE AG since July 12, 2016. He served as a Member of Supervisory Board at Lek Pharmaceuticals d.d. (Lek d.d.) since October 2008. He served as a Director of Eon Labs, Inc. since July 21, 2005. He served as a Director of Alvogen and Mipharm S.p.A. He served as Member of the Executive Committee of Novartis from January 1, 2006 to 2010. Dr. Rummelt received Executive Training in General Management and Leadership from IMD, INSEAD and Harvard Business School in Boston. He graduated with a Ph.D in Pharmaceutical Sciences from the University of Erlangen-Nürnberg, Germany in 1983.


We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.